【摘要】 目的 評價大分割適形放射治療對腹膜后軟組織腫瘤術后患者的治療作用。 方法 對1998年10月-2003年4月收治的16例腹膜后軟組織急性腫瘤術后患者行大分割適形放射治療，設計臨床靶區等效生物劑量為55～62 Gy，觀察放療后2、5年局部控制率、生存率和無病生存情況。 結果 2、5年局部控制率較未行放療患者明顯提高并和其他放射治療方式達到較高治療劑量者近似；遠期生存無改善，無病生存率較未行放療患者有提高。 結論 大分割適形放射治療方式對腹膜后軟組織急性腫瘤術后患者有較好的局部控制作用，無瘤生存率有提高，遠期生存無改善，無嚴重的遠期放療后遺癥。【Abstract】 Objective To observe the effect of high-dose three-dimensional conformal radiotherapy combined with surgery on primary retroperitoneal soft tissue sarcoma. Methods A total of 16 patients with primary retroperitoneal soft tissue sarcoma underwent high-dose three-dimensional conformal radiotherapy after sarcoma excision from October 1998 to April 2003. The biologically effective dose was 55-62 Gy for CTV. The local control rate and long-term survival rate and disease free survival after 2 and 5 years were observed. Results The local control rate obviously raised in these patients after 2 and 5 years; but the long-term survival rate didn’t improve and the disease free survival improved in these patients compared with those wasn’t radiated. Conclusion High-dose three-dinensional comfomal radiotherapy is effective on the patients with retroperitoneal soft tissue sarcoma in local control rate and disease free survival, but long-term survival rate is not improved and the side-effect is not serious.
摘要:目的:探討鼻咽癌放療后程同步輔以小劑量順鉑增敏的近期療效,并與常規治療和后程加速超分割放射治療進行比較。方法:選取98例Ⅱ～Ⅳ期鼻咽癌患者,隨機分為常規治療組(簡稱T1組,32例)、后程加速超分割治療組(簡稱T2組,32例)和順鉑加后程加速超分割治療組(簡稱T3組,34例),并對治療效果進行比較。 結果:1組鼻咽部腫瘤消除率為75.0%(24／32),頸部淋巴結消除率為87.5%(28/32);T2組鼻咽部腫瘤消除率為87.5%(28／32),頸部淋巴結消除率為84.4%(27/32);T3組鼻咽部腫瘤消除率為97.1%(33／34),頸部淋巴結消除率為91.2%(31/34)。進行兩兩比較,均為P＜0.05,有統計學意義,療效:T3 組＞T2 組＞T1組。治療副作用有增加(P＞0.05),但無統計學意義。 結論:小劑量順鉑加后程加速超分割治療鼻咽癌,可以達到較常規治療更好的近期治療效果。Abstract: Objective: To study the later therapeutic efficacy of nasopharyngeal carcinoma in late course accelerated fractionation (LCAF) radiotherapy and low dose cisplatin, at same time compare with conventional fractionation and LCAF. Methods: Ninetyeight cases with stage ⅡⅣ of nasopharyngeal carcinoma were randomly assigned to three groups: conventional fractionation (T1), LCAF (T2), LCAF and low dose cisplatin (T3). At the end of treatment, therapeutic efficacy was compared with each other. Results: The survey periods was 3 months. Comlete response rate (CR) for groups T1, T2 and T3 was 75.0% (24／32), 87.5% (28／32) and 97.1% (33／34), respectively; the group treated with LCAF and cisplatin had highest effective later therapeutic efficacy than other groups. Lymph node of neck of group T3 got better control, although its side effects were more serious, but no significant difference was found among three group. Conclusion: Combined treatment of LCAF radiotherapy and low dose cisplatin has better later therapeutic efficacy on tumor control in patients with nasopharyngeal carcinoma
